Pharmacokinetics and tissue distribution of Yigong San in rats.

Pharmacokinetics Tissue distribution UPLC-MS/MS Yigong San (YGS)

Journal

Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310

Informations de publication

Date de publication:
08 May 2024
Historique:
received: 02 03 2024
revised: 28 04 2024
accepted: 05 05 2024
medline: 11 5 2024
pubmed: 11 5 2024
entrez: 10 5 2024
Statut: aheadofprint

Résumé

In traditional Chinese medicine (TCM), Yigong San (YGS) is mainly used to treat dyspepsia caused by deficiency of spleen and stomach qi. Although the chemical composition and bioactivity of YGS has been well studied, the main in vivo compounds and their distribution in tissues still need to be made clearer. To elucidate the pharmacokinetic profiles and tissue distribution of eight main compounds of YGS in rats, and provide a reference for clinical application and new drug development. UPLC-Q-Exactive-Orbitrap-MS was used to qualitatively characterize the parent compounds and their metabolites in the plasma of rats after oral administration of YGS. A sensitive, reliable, and accurate ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method using UPLC-AB Sciex QTRAP 5500 MS was established to quantitatively determine eight main compounds of YGS in rat plasma and tissues, including liquiritin, isoliquiritin, hesperidin, ginsenosides Rb The mean area under the concentration-time curve (AUC) values of ginsenoside Rb All main compounds of YGS, i.e., liquiritin, isoliquiritin, hesperidin, ginsenosides Rb

Identifiants

pubmed: 38729539
pii: S0378-8741(24)00598-1
doi: 10.1016/j.jep.2024.118299
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118299

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☑The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Auteurs

Jing Wang (J)

School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China.

Zhihao Zhu (Z)

School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China.

Lan Yang (L)

School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China.

Yudi Nie (Y)

School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China.

Siqi Liu (S)

School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China.

Dan Li (D)

Hebei Shineway Pharmaceutical Co., Ltd., Yingbin Street, Langfang, Hebei, 065201, China. Electronic address: ldyeah@yeah.net.

Jincai Hou (J)

Hebei Shineway Pharmaceutical Co., Ltd., Yingbin Street, Langfang, Hebei, 065201, China. Electronic address: jincaihou@126.com.

Rufeng Wang (R)

School of Life Sciences, Beijing University of Chinese Medicine, Liangxiang University Town, Yangguang South Street, Fangshan District, Beijing, 102488, China. Electronic address: wangrufeng@tsinghua.org.cn.

Classifications MeSH